<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568267</url>
  </required_header>
  <id_info>
    <org_study_id>RXDX-101-02</org_study_id>
    <nct_id>NCT02568267</nct_id>
  </id_info>
  <brief_title>Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)</brief_title>
  <acronym>STARTRK-2</acronym>
  <official_title>An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignyta, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ignyta, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101)
      for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene
      rearrangement. Patients will be assigned to different baskets according to tumor type and
      gene rearrangement. NSCLC and mCRC will be the main patient populations of interest
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Tumor Response</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS Progression-free Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by blinded independent central review (BICR) using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Approximately 30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by Kaplan-Meier method</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Lymphoma, Large-Cell, Anaplastic</condition>
  <condition>Melanoma</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Papillary Thyroid Cancer</condition>
  <condition>Primary Brain Tumors</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Sarcomas</condition>
  <condition>Salivary Gland Cancers</condition>
  <condition>Adult Solid Tumor</condition>
  <arm_group>
    <arm_group_label>NTRK1/2/3-rearranged NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROS1-rearranged NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK- or ROS1-rearranged NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with CNS-only progression previously treated with crizotinib
Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTRK/1/2/3-rearranged mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROS1-rearranged mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK-rearranged mCRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTRK1/2/3-rearranged other solid tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROS1-rearranged other solid tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK-rearranged other solid tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>TrkA/B/C, ROS1, and ALK inhibitor</description>
    <arm_group_label>NTRK1/2/3-rearranged NSCLC</arm_group_label>
    <arm_group_label>ROS1-rearranged NSCLC</arm_group_label>
    <arm_group_label>ALK- or ROS1-rearranged NSCLC</arm_group_label>
    <arm_group_label>NTRK/1/2/3-rearranged mCRC</arm_group_label>
    <arm_group_label>ROS1-rearranged mCRC</arm_group_label>
    <arm_group_label>ALK-rearranged mCRC</arm_group_label>
    <arm_group_label>NTRK1/2/3-rearranged other solid tumor</arm_group_label>
    <arm_group_label>ROS1-rearranged other solid tumor</arm_group_label>
    <arm_group_label>ALK-rearranged other solid tumor</arm_group_label>
    <other_name>RXDX-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically-confirmed diagnosis of locally advanced or
             metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement

             - Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a
             gene rearrangement of interest may be eligible provided they meet all other
             inclusion/exclusion criteria

          -  For patients enrolled via local molecular testing, an archival or fresh tumor tissue
             (unless medically contraindicated) is required to be submitted for independent
             central molecular testing at Ignyta's CLIA laboratory post-enrollment

          -  Measurable or evaluable disease

          -  Patients with CNS involvement, including leptomeningeal carcinomatosis, which is
             either asymptomatic or previously-treated and controlled, are allowed

          -  Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1,
             or ALK inhibitors in patients who have tumors that harbor those respective gene
             rearrangements)

             - Note: prior treatment with crizotinib is permitted in ALK- or ROS1-rearranged NSCLC
             patients presenting with CNS-only progression

          -  At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior
             chemotherapy or small molecule targeted therapy

          -  At least 4 weeks must have elapsed since completion of antibody-directed therapy

          -  Prior radiotherapy is allowed if more than 14 days have elapsed since the end of
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Adequate organ function as defined per protocol

          -  Ability to swallow entrectinib intact

          -  Other protocol specified criteria

        Exclusion Criteria:

          -  Current participation in another therapeutic clinical trial

          -  Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in
             patients who have tumors that harbor those respective gene rearrangements

             - Note: prior treatment with crizotinib is permitted in ALK- or ROS1-rearranged NSCLC
             patients presenting with CNS-only progression

          -  History of other previous cancer that would interfere with the determination of
             safety or efficacy

          -  Incomplete recovery from any surgery

          -  History of non-pharmacologically induced prolonged QTc interval

          -  History of additional risk factors for torsade de pointes

          -  Peripheral neuropathy Grade ≥ 2

          -  Known active infections

          -  Active gastrointestinal disease or other malabsorption syndromes

          -  Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase
             inhibitor-induced pneumonitis

          -  Other protocol specified criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edna Chow Maneval, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ignyta, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignyta Inc.</last_name>
    <phone>1-844-782-7875</phone>
    <email>STARTRKtrials@ignyta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Weiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Fakih, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic Medical Group</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Sigal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Bazhenova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine College of Medicine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Seery, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Kaiser Permanente</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Polikoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Mount Zion Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin Blakely, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center LLC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamalesh Sankhala, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Doebele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Haura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida - Maroone Cancer Center</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Samuel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petros Nikolinakos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conor Steuer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioana Bonta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Acoba, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, S.C.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Hooberman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Ahn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital / Beth Israel Deaconess Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Farago, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Krauss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detriot</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirish Gadgeel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saiama Waqar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Chamberlin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates, PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Drilon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Shepard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSU - James Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Otterson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Pollock, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Taylor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Crilley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Nemunaitis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Chiorean, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wheaton Franciscan Cancer Care-All Saints</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Treisman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Maria Aslam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Craig Underhill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Christian Rolfo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Kent Ridge</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Cheng Ean Chee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Simon Pacey</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 13, 2016</lastchanged_date>
  <firstreceived_date>October 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Entrectinib</keyword>
  <keyword>RXDX-101</keyword>
  <keyword>TrkA</keyword>
  <keyword>TrkB</keyword>
  <keyword>TrkC</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>ROS1</keyword>
  <keyword>ALK</keyword>
  <keyword>Trk Fusions</keyword>
  <keyword>NTRK Gene Rearrangements</keyword>
  <keyword>ROS1 Fusions</keyword>
  <keyword>ROS1 Gene Rearrangements</keyword>
  <keyword>ALK Fusions</keyword>
  <keyword>ALK Gene Rearrangements</keyword>
  <keyword>Basket study</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Salivary gland cancers</keyword>
  <keyword>Primary brain tumors</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Sarcomas</keyword>
  <keyword>Papillary thyroid cancer</keyword>
  <keyword>Renal cell cancer</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Head &amp; Neck cancers</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Neuroendocrine tumors</keyword>
  <keyword>Anaplastic Large Cell Lymphoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
